Rapid Test Lateral Flow Immunoassays

Lateral flow immunoassay (LFIA) or known as rapid test, are simple, rapid, and cheap assays for detecting and quantifying various analytes such as pathogens, hormone, protein, drugs, or contaminant in water and food. This assay is commonly used as a point of care test, which can be used by many people and performed near the patient or in the place where health care is provided. Furthermore, this assay is widely used in in vitro diagnostic (IVD) industry. One of the LFIA assay is a colloidal gold-base LFIA. This assay use a  gold nanoparticle as a label for detection.

CEPAD

•The rapid antigen test that we have developed is CEPAD in collaboration with PT.Pakar Biomedika Indonesia and PT. Tekad Mandiri Citra, which can detect the Nucleocapsid protein as a structural protein of the SARS-CoV-2 virus.

•From the COVID-19 pandemic, we have learned how to develop an antigen-based rapid tests that can diagnose COVID-19 and can help to tracking and breaking the chain of transmission of the SARS-CoV-2 virus, especially in Indonesia.

•The antigen-based rapid tests explicitly meets the ASSURED (Affordable, Sensitive, Specific, User Friendly, Rapid and Robust, Equipment free and Deliverable to end user) criteria.

•Unpad is the only university that creates antigen-based rapid tests in Indonesia, and CEPAD has a sensitivity rate 96.7% and specificity rate 100%.

Saliva-Test Antigen

We also developed the saliva-based antigen rapid test for COVID-19 detection. The validation test process of this assay was still conducted.

Development

Now, we focus on developing rapid test kits based on antigens and antibodies to diagnose other infectious diseases.

Labelling Gold Nano Particles

For usage in lateral flow applications, Colloidal Gold has been specially developed. The wide size distribution of the suspension, which is produced at OD 1, has been found our scientists to enhance conjugation stability and assay sensitivity.